United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

almus pharmaceuticals ltd - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

macleods pharma uk ltd - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 40mg

United States - English - NLM (National Library of Medicine)

rebel distributors corp - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 40 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. for those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pediatric indication and usage information in pediatric patients ages five years and older with erosive esophagitis associated with gerd is approved for wyeth pharmaceuticals inc.’s pantoprazole sodium delayed-release tablets. however, due to wyeth pharmaceuticals inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime hear

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

torrent pharma (uk) ltd - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

torrent pharma (uk) ltd - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 40mg

Philippines - English - FDA (Food And Drug Administration)

vitalis s.a.c.i; importer: pan-ject pharmaceuticals corp.; distributor: pan-ject pharmaceuticals corp. - neostigmine (as methylsulfate) - solution for injection (im/iv/sc) - 0.5mg/ml

Kenya - English - Pharmacy and Poisons Board

alkem laboratories 167/1 mahatma gandhi udyog nagar dabhel daman-396 - pantoprazole (as sodium sesquihydrate). - injection - pantoprazole (as sodium sesquihydrate) 40mg - drugs for peptic ulcer and gastro-oesophageal

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 25 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.